Should you buy ACADIA Pharmaceuticals (ACAD)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Strong Quality Metrics→Stable
- Wide Dislocation Favorable Asymmetry→Stable
- Technical Downtrend Hard Block→Stable
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Dislocation Favorable Asymmetry
Trip ifPrice rises above $26.00, leaving less than 10% headroom to the $28.48 target.
- P2Technical Downtrend Hard Block
Trip ifThe 50-day moving average crosses above the 200-day moving average and price sustains above the 200-day for more than 30 consecutive trading days.
- P3Product Revenue Concentration
Trip ifA third commercial product or major label expansion contributes more than $50 million in quarterly revenue.
- P4Strong Quality Metrics
Trip ifNet margin falls below 20% for 2 consecutive quarters.
How the engine reached this verdict
TrendMatrix's engine output for ACADIA Pharmaceuticals Inc. (ACAD) is SELL_IF_HOLDING with high conviction, score 5.2/10 at $25.86. The F-path SELL output reflects an overall score of 3.7 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 0.80 is supplementary context, not the trigger.
The dominant failed gate is reward-to-risk at 0.8 vs threshold 1.5. SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:5.1>=4.5.
On the bull side: Recent Analyst detected in news; Recent Analyst Cluster(3) detected in news. On the bear side: Concentration risk — Product: NUPLAZID and DAYBUE; Concentration risk — Pipeline: remlifanserin RADIANT Phase 2; Earnings expected to decline ~60% (cyclical peak). Active engine warnings: V8: Cyclical trap - fwd PE 29x vs trail 12x (2.5x), V9 Gate Failed: ASYMMETRY:0.8<1.5@spot.
The engine's exit framework anchors to a tactical sell band near $25.86, with structural invalidation at $24.15. The asymmetric R:R against a reversal hypothesis is 0.80 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ACAD — 10-dimension breakdown →
Bull case
- ▸Recent Analyst detected in news
- ▸Recent Analyst Cluster(3) detected in news
Bear case
- ▸Concentration risk — Product: NUPLAZID and DAYBUE
- ▸Concentration risk — Pipeline: remlifanserin RADIANT Phase 2
- ▸Earnings expected to decline ~60% (cyclical peak)